Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of Melan-A-specific, tumor-reactive CTL in melanoma patients

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7084-7092

  Palermo, Belinda ^a   Del Bello, Duilia ^a   Sottini, Alessandra ^d   Serana, Federico ^d   Ghidini, Claudia ^d   Gualtieri, Novella ^a   Ferraresi, Virginia ^a   Catricalà, Caterina ^b   Belardelli, Filippo ^c   Proietti, Enrico ^c   Natali, Pier Giorgio ^a,e   Imberti, Luisa ^d   Nisticò, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b S Gallicano Dermatological Institute   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d Diagnostics Department   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; GP100 209 217; MELAN A; MELAN A 26 35; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CANCER VACCINE; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; MLANA PROTEIN, HUMAN; SUBUNIT VACCINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; GENE ACTIVATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; LEUKOCYTE ACTIVATION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; ANTIBODY AFFINITY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; K562 CELL LINE; MULTIMODALITY CANCER THERAPY;

ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DACARBAZINE; EPITOPES, T-LYMPHOCYTE; HUMANS; K562 CELLS; MART-1 ANTIGEN; MELANOMA; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 77956920709     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1326     Document Type: Article

References (48)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
2. Old LJ. Cancer vaccines: an overview. Cancer Immun 2008;8:1-4.
3. Jandus C, Speiser D, Romero P. Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res 2009;22:711-23.
4. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
6. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13:5256-61.
7. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
8. Bracci L, Moschella F, Sestili P, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007;13:644-53.
9. Proietti E, Greco G, Garrone B, et al. Importance of cyclophosphamide- induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998;101:429-41.
10. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.
11. Nisticò P, Capone I, Palermo B, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009;124:130-9.
12. Nikolich-Zugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004;4:123-32.
13. Speiser DE, Baumgaertner P, Barbey C, et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006;177:1338-48.
14. Connerotte T, Van Pel A, Godelaine D, et al. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res 2008;68:3931-40.
15. Monsurrò V, Nielsen MB, Perez-Diez A, et al. Kinetics of TCR use in response to repeated epitope-specific immunization. J Immunol 2001;166:5817-25.
16. Wieckowski S, Baumgaertner P, Corthesy P, et al. Fine structural variations of αβTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol 2009;183:5397-406.
17. Palermo B, Campanelli R, Mantovani S, et al. Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. Eur J Immunol 2001;31:412-20.
18. Martin R, Howell MD, Jaraquemada D, et al. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 1991;173:19-24.
19. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455-500.
20. Lefranc MP, Pommié C, Ruiz M, et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 2003;27:55-77.
21. McKee MD, Roszkowski JJ, Nishimura MI. T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 2005;3:35.
22. Serana F, Sottini A, Caimi L, et al. Identification of a public CDR3 motif and a biased utilization of T-cell receptor Vβ and Jβ chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients. J Transl Med 2009;7:21.
23. + T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009;206:849-66.
24. Stuge TB, Holmes SP, Saharan S, et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med 2004;1:149-60.
25. Colombetti S, Fagerberg T, Baumgärtner P, et al. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. J Immunol 2006;176:6560-7.
26. Takase H, Yu CR, Mahdi RM, et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int Immunol 2005;17:1131-40.
27. + T cells in the circulation but not in the tumor site. J Immunol 2006;177:1670-8.
28. + T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003;63:2535-45.
29. Ahmed M, Lanzer KG, Yager EJ, Adams PS, Johnson LL, Blackman MA. Clonal expansions and loss of receptor diversity in the naive CD8 T cell repertoire of aged mice. J Immunol 2009;182:784-92.
30. Derré L, Bruyninx M, Baumgaertner P, et al. Distinct sets of αβ TCRs confer similar recognition of tumor antigen NY-ESO-1 157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A 2008;105:15010-5.
31. Cole DK, Yuan F, Rizkallah PJ, et al. Germline-governed recognition of a cancer epitope by an immunodominant human T-cell receptor. J Biol Chem 2009;284:27281-9.
32. Bioley G, Guillaume P, Luescher I, et al. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors. J Immunother 2009;32:161-8.
33. Beyer M, Karbach J, Mallmann MR, et al. Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy". Cancer Res 2009;69:4346-54.
34. Messaoudi I, Guevara Patiño JA, Dyall R, LeMaoult J, Nikolich-Zugich J. Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science 2002;298:1797-800.
35. Kedzierska K, La Gruta NL, Stambas J, Turner SJ, Doherty PC. Tracking phenotypically and functionally distinct T cell subsets via T cell repertoire diversity. Mol Immunol 2008;45:607-18.
36. + T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007;204:2473-85.
37. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
38. Cornberg M, Chen AT, Wilkinson LA, et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J Clin Invest 2006;116:1443-56.
39. Sanada M, Takagi Y, Ito R, Sekiguchi M. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair 2004;3:413-20.
40. Bonmassar E, Bonmassar A, Vadlamudi S, Goldin A. Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug. Proc Natl Acad Sci U S A 1970;66:1089-95.
41. Grohmann U, Puccetti P, Belladonna ML, et al. Multiple point mutations in an endogenous retroviral gene confer high immunogenicity on a drug-treated murine tumor. J Immunol 1995;154:4630-41.
42. Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005;102:16013-8.
43. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008;29:848-62.
44. Ramsey C, Rubinstein MP, Kim DM, Cho JH, Sprent J, Surh CD. The lymphopenic environment of CD132 (common γ-chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol 2008;180:5320-6.
45. + T cells. Proc Natl Acad Sci U S A 2004;101:15154-9.
46. Vezys V, Masopust D, Kemball CC, et al. Continuous recruitment of naive T cells contributes to heterogeneity of antiviral CD8 T cells during persistent infection. J Exp Med 2006;203:2263-9.
47. Davenport MP, Fazou C, McMichael AJ, Callan MF. Clonal selection, clonal senescence, and clonal succession: the evolution of the T cell response to infection with a persistent virus. J Immunol 2002;168:3309-17.
48. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007;204:1405-16.